Imiglucerase
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 314 publications
Quantitative and Comparative Assessment of Recombinant Human β-Glucocerebrosidase Uptake Bioactivity Using a Stable hMMR-Expressing CHO Cell Model.
Journal: Molecules (Basel, Switzerland)
Published: November 27, 2025
Maternal and Fetal Outcomes in Imiglucerase-Treated Patients With Gaucher Disease: Real-World Evidence From the International Collaborative Gaucher Group (ICGG) Gaucher Registry Pregnancy Sub-Registry.
Journal: Journal of inherited metabolic disease
Published: October 09, 2025
Ten-Year Follow-Up of Taliglucerase Alfa in Type 1 Gaucher Disease: Real-World Evidence from Albania.
Journal: Journal of clinical medicine
Published: September 02, 2025
The global impact of imiglucerase therapy in children with Gaucher disease types 1 and 3: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Journal: Orphanet journal of rare diseases
Published: August 07, 2025
Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report.
Journal: Frontiers in pediatrics
Published: May 14, 2025
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Journal: PharmacoEconomics - open
Published: April 08, 2025
Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease.
Journal: Frontiers in medicine
Published: January 30, 2025
Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease
Journal: Terapevticheskii arkhiv
Published: January 23, 2025
Real-world experience of switching to taliglucerase among patients with Gaucher disease in Québec: A case series.
Journal: Molecular genetics and metabolism reports
Published: January 03, 2025
A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration.
Journal: Molecular genetics & genomic medicine
Published: December 11, 2024
Systemically delivered lipid nanoparticle-mRNA encoding lysosomal acid β-glucosidase restores the enzyme deficiency in a murine Gaucher disease model.
Journal: Gene therapy
Published: December 09, 2024
Case Report: Clinical case analysis of gaucher disease management in a resource-limited setting: a single center experience from Kashigar, Xinjiang Uygur Autonomous Region, the Western China.
Journal: Frontiers in pediatrics
Published: November 18, 2024
Last Updated: 04/28/2026